340 related articles for article (PubMed ID: 22058153)
21. The alteration of protein prenylation induces cardiomyocyte hypertrophy through Rheb-mTORC1 signalling and leads to chronic heart failure.
Xu N; Guan S; Chen Z; Yu Y; Xie J; Pan FY; Zhao NW; Liu L; Yang ZZ; Gao X; Xu B; Li CJ
J Pathol; 2015 Apr; 235(5):672-85. PubMed ID: 25385233
[TBL] [Abstract][Full Text] [Related]
22. Indoleamine 2,3-Dioxygenase 1 (IDO1) Promotes Cardiac Hypertrophy via a PI3K-AKT-mTOR-Dependent Mechanism.
Liu Y; Li S; Gao Z; Li S; Tan Q; Li Y; Wang D; Wang Q
Cardiovasc Toxicol; 2021 Aug; 21(8):655-668. PubMed ID: 34021461
[TBL] [Abstract][Full Text] [Related]
23. KLK11 promotes the activation of mTOR and protein synthesis to facilitate cardiac hypertrophy.
Wang Y; Liao H; Wang Y; Zhou J; Wang F; Xie Y; Zhao K; Gao W
BMC Cardiovasc Disord; 2021 May; 21(1):266. PubMed ID: 34059001
[TBL] [Abstract][Full Text] [Related]
24. Determination of the catalytic activity of LEOPARD syndrome-associated SHP2 mutants toward parafibromin, a bona fide SHP2 substrate involved in Wnt signaling.
Noda S; Takahashi A; Hayashi T; Tanuma S; Hatakeyama M
Biochem Biophys Res Commun; 2016 Jan; 469(4):1133-9. PubMed ID: 26742426
[TBL] [Abstract][Full Text] [Related]
25. Role of ERK1/2 signaling in congenital valve malformations in Noonan syndrome.
Krenz M; Gulick J; Osinska HE; Colbert MC; Molkentin JD; Robbins J
Proc Natl Acad Sci U S A; 2008 Dec; 105(48):18930-5. PubMed ID: 19017799
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of the Gab2/PI3K/mTOR signaling ameliorates myeloid malignancy caused by Ptpn11 (Shp2) gain-of-function mutations.
Liu W; Yu WM; Zhang J; Chan RJ; Loh ML; Zhang Z; Bunting KD; Qu CK
Leukemia; 2017 Jun; 31(6):1415-1422. PubMed ID: 27840422
[TBL] [Abstract][Full Text] [Related]
27. Mediating ERK 1/2 signaling rescues congenital heart defects in a mouse model of Noonan syndrome.
Nakamura T; Colbert M; Krenz M; Molkentin JD; Hahn HS; Dorn GW; Robbins J
J Clin Invest; 2007 Aug; 117(8):2123-32. PubMed ID: 17641779
[TBL] [Abstract][Full Text] [Related]
28. Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature.
De Rocca Serra-Nédélec A; Edouard T; Tréguer K; Tajan M; Araki T; Dance M; Mus M; Montagner A; Tauber M; Salles JP; Valet P; Neel BG; Raynal P; Yart A
Proc Natl Acad Sci U S A; 2012 Mar; 109(11):4257-62. PubMed ID: 22371576
[TBL] [Abstract][Full Text] [Related]
29. Clinical and mutation profile of pediatric patients with RASopathy-associated hypertrophic cardiomyopathy: results from a Chinese cohort.
Chen H; Li X; Liu X; Wang J; Zhang Z; Wu J; Huang M; Guo Y; Li F; Wang X; Fu L
Orphanet J Rare Dis; 2019 Feb; 14(1):29. PubMed ID: 30732632
[TBL] [Abstract][Full Text] [Related]
30. Shp2 knockdown and Noonan/LEOPARD mutant Shp2-induced gastrulation defects.
Jopling C; van Geemen D; den Hertog J
PLoS Genet; 2007 Dec; 3(12):e225. PubMed ID: 18159945
[TBL] [Abstract][Full Text] [Related]
31. RAS signaling pathway mutations and hypertrophic cardiomyopathy: getting into and out of the thick of it.
Gelb BD; Tartaglia M
J Clin Invest; 2011 Mar; 121(3):844-7. PubMed ID: 21339640
[TBL] [Abstract][Full Text] [Related]
32. Endothelin-1 induces myofibrillar disarray and contractile vector variability in hypertrophic cardiomyopathy-induced pluripotent stem cell-derived cardiomyocytes.
Tanaka A; Yuasa S; Mearini G; Egashira T; Seki T; Kodaira M; Kusumoto D; Kuroda Y; Okata S; Suzuki T; Inohara T; Arimura T; Makino S; Kimura K; Kimura A; Furukawa T; Carrier L; Node K; Fukuda K
J Am Heart Assoc; 2014 Nov; 3(6):e001263. PubMed ID: 25389285
[TBL] [Abstract][Full Text] [Related]
33. Pinoresinol diglucoside (PDG) attenuates cardiac hypertrophy via AKT/mTOR/NF-κB signaling in pressure overload-induced rats.
Chen Y; Pan R; Zhang J; Liang T; Guo J; Sun T; Fu X; Wang L; Zhang L
J Ethnopharmacol; 2021 May; 272():113920. PubMed ID: 33607200
[TBL] [Abstract][Full Text] [Related]
34. Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice.
Condorelli G; Drusco A; Stassi G; Bellacosa A; Roncarati R; Iaccarino G; Russo MA; Gu Y; Dalton N; Chung C; Latronico MV; Napoli C; Sadoshima J; Croce CM; Ross J
Proc Natl Acad Sci U S A; 2002 Sep; 99(19):12333-8. PubMed ID: 12237475
[TBL] [Abstract][Full Text] [Related]
35. Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy.
Tsybouleva N; Zhang L; Chen S; Patel R; Lutucuta S; Nemoto S; DeFreitas G; Entman M; Carabello BA; Roberts R; Marian AJ
Circulation; 2004 Mar; 109(10):1284-91. PubMed ID: 14993121
[TBL] [Abstract][Full Text] [Related]
36. Gain-of-function mutations in the gene encoding the tyrosine phosphatase SHP2 induce hydrocephalus in a catalytically dependent manner.
Zheng H; Yu WM; Waclaw RR; Kontaridis MI; Neel BG; Qu CK
Sci Signal; 2018 Mar; 11(522):. PubMed ID: 29559584
[TBL] [Abstract][Full Text] [Related]
37. Altered C10 domain in cardiac myosin binding protein-C results in hypertrophic cardiomyopathy.
Kuster DWD; Lynch TL; Barefield DY; Sivaguru M; Kuffel G; Zilliox MJ; Lee KH; Craig R; Namakkal-Soorappan R; Sadayappan S
Cardiovasc Res; 2019 Dec; 115(14):1986-1997. PubMed ID: 31050699
[TBL] [Abstract][Full Text] [Related]
38. Low-dose Dasatinib Ameliorates Hypertrophic Cardiomyopathy in Noonan Syndrome with Multiple Lentigines.
Yi JS; Perla S; Huang Y; Mizuno K; Giordano FJ; Vinks AA; Bennett AM
Cardiovasc Drugs Ther; 2022 Aug; 36(4):589-604. PubMed ID: 33689087
[TBL] [Abstract][Full Text] [Related]
39. A Disintegrin and Metalloprotease-22 Attenuates Hypertrophic Remodeling in Mice Through Inhibition of the Protein Kinase B Signaling Pathway.
Ren L; Wu C; Yang K; Chen S; Ye P; Wu J; Zhang A; Huang X; Wang K; Deng P; Ding X; Chen M; Xia J
J Am Heart Assoc; 2018 Jan; 7(2):. PubMed ID: 29358191
[TBL] [Abstract][Full Text] [Related]
40. Focal adhesion kinase governs cardiac concentric hypertrophic growth by activating the AKT and mTOR pathways.
Clemente CF; Xavier-Neto J; Dalla Costa AP; Consonni SR; Antunes JE; Rocco SA; Pereira MB; Judice CC; Strauss B; Joazeiro PP; Matos-Souza JR; Franchini KG
J Mol Cell Cardiol; 2012 Feb; 52(2):493-501. PubMed ID: 22056317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
